Integra LifeSciences reports Q3 adjusted EPS 59c, consensus 56c

Integra LifeSciences reported Q3 adjusted EPS of 59c, beating consensus of 56c, while revenue was $411.2M, slightly missing the $412.1M estimate. CEO Stuart Essig noted mixed results across their portfolio, with strong cash flow and completed debt refinancing. Analysts have recently lowered price targets for the company.

Original reporting
Published Oct 21, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Neutral
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$IARTNeutralMed
01

Why it matters

Earnings beat may provide short‑term support, but operational disruptions and revenue miss could limit upside.

02

Market read

First‑report earnings release for a mid‑cap med‑tech company; modest impact on sector.

03

What to watch

Potential impact of the $7M Cincinnati disruption on future margins.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Integra LifeSciences operates in specialty surgery and tissue reconstruction, recently completed a debt refinancing.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Integra LifeSciences reported Q3 adjusted EPS of $0.59 versus consensus $0.56 and revenue of $411.2M versus $412.1M consensus.

Expected impact

likely modest upward pressure as the market prices in the EPS beat

Evidence & confidence

The earnings surprise is small and the revenue shortfall is minimal, suggesting limited but positive price movement.

Market effects

Healthcare devices sector sees a mixed earnings season with a few modest beats.

U.S. markets may see slight positive bias in related med‑tech stocks.

Limited; primarily affects U.S. listed med‑tech equities.

Counterpoint

The revenue miss could signal underlying demand weakness, outweighing the EPS beat.

Key entities

  • Stuart Essig

    Chairman and CEO of Integra LifeSciences, provided commentary on Q3 results.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.